
Aktis Oncology Announces Completion of $84M Series A+ Financing
Aktis Oncology, a biotechnology company focused on the discovery and development of novel targeted alpha radiopharmaceuticals to treat solid tumors, announced the completion of an
Aktis Oncology, a biotechnology company focused on the discovery and development of novel targeted alpha radiopharmaceuticals to treat solid tumors, announced the completion of an